75results about How to "Reduced uptake" patented technology

The present invention relates to a composition for controlling viability of a tissue including a potassium channel opener or adenosine receptor agonist, a compound for inducing local anaesthesia and a compound for reducing the uptake of water by a cell in the tissue. The present invention also realtes to the use of the composition accordng to the invention for controlling viability of a tissue.

Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.

A system that applies strips of material, such as labels, to a cylindrical body, such as a bottle. The system includes a vacuum cylinder that holds the labels. The vacuum cylinder rotates bringing the labels into contact with a rotary application head that applies hot melt adhesive to the passing labels. The rotary application head includes a feed channel system that cooperates with a mask cylinder to controllably apply the adhesive. The adhesive covered label then is fixed to a bottle or other device that is rotating in a carousel.

The present invention provides methods for manufacturing heat treated products involving the use of probiotic bacteria, e.g. lactic acid bacteria and/or Bifidobacteria, cultures of such bacteria, supernatant from such cultures, and/or concentrates of such supernatant and/or fractions of such supernatant. The invention further provides heat treated products of such processes and their use for regulation of cellular uptake of fat and/or triglycerides and/or body weight management or weight reduction and/or redistribution of fat and/or reduction in visceral and/or abdominal fat deposition in a subject.

The invention discloses a special composite coating diaphragm for a lithium battery. The special composite coating diaphragm comprises a microporous membrane, resin layers, ceramic layers and acrylicadhesive layers; the special composite coating diaphragm is characterized in that the resin layers coat the upper surface and the lower surface of the microporous membrane; one ceramic layer coats theouter side of each resin layer; one acrylic adhesive layer coats the outside of each ceramic layer; first micropores are formed in the microporous membrane; second micropores are formed in each resinlayer; third micropores are formed in each ceramic layer; and fourth micropores are formed in each acrylic adhesive layer. A preparation method of the special composite coating diaphragm for the lithium battery comprises the following steps of surface modification of boehmite alumina, preparation of the microporous membrane, preparation of a polymer composite membrane, preparation of modified boehmite alumina slurry, coating of the modified boehmite alumina slurry and bonding forming of an acrylic adhesive, thereby obtaining the special composite coating diaphragm for the lithium battery. According to the composite coating diaphragm, the security problem of a high-energy density battery core can be well solved.

An electroluminescent display or lighting product incorporates a panel comprising a collection of distinct light-emitting elements formed on a substrate. A plurality of distinct local seals are formed over respective individual light-emitting elements or groups of light-emitting elements. Each local seal is formed by depositing a low melting temperature glass powder suspension or paste using inkjet technology, and fusing the glass powder using a scanning laser beam having a tailored beam profile. The local seal may be used in conjunction with a continuous thin film encapsulation structure. Optical functions can be provided by each local seal, including refraction, filtering, color shifting, and scattering.

Mycotoxin-deactivating aptamers, especially DNA aptamers, bind to mycotoxins in feed and feed ingredients resulting in the reduction or elimination of toxic and carcinogenic effects of mycotoxins. The invention also discloses a composition comprising a mycotoxin-deactivating aptamer, a binding agent, a biotransforming agent and an antioxidant for detoxifying mycotoxins in feeds. In addition, the invention teaches the methods of preparing said mycotoxin-deactivating aptamer-based composition and also the methods of using it as a feed additive. Furthermore, the invention relates to the use of said mycotoxin-deactivator/s alone, or in a composition comprising said aptamers and other mycotoxin-detoxifying agents, in feeds and feed ingredients for detoxifying the major mycotoxins such as aflatoxins, deoxynivalenol, zearalenone, fumonisins and ochratoxin A.

The invention aims to provide a liquid absorption fiber. The fiber comprises a polymer represented by the following structural form shown in the description, wherein R is at least one selected from a group consisting of -NH2, -OCH2CH2OH, -OCH2CH2CH2OH, -OH, -ONa, -OK and -OCa; m, n and p respectively represent the quantity percentages of corresponding repeating units in a polymer molecule, and meet the following relational expression: m+n+p=1, p/(m+n+p)=0.05 to 0.30; when the degree of substitution D is defined to be m/(m+n+p): the total degree of substitution of the fiber Ds is 0.09 to 0.8, and the value of the degree of substitution Do of the polymer at the center point of the cross section of the fiber/the degree of substitution Dx of the polymer on the edge of the cross section of the fiber is 0 to 0.98. By the use of a simple process, the antibacterial performance, the liquid absorption property and the like of the fiber are improved by controlling the proportions of the repeating units with different substituent groups in the polymer contained in the fiber and enabling the degree of substitution of the outer side (edge) of the fiber to be greater than that of the inside (center) of the fiber; the fiber suitable for clinical application, particularly applicable in the aspects such as hemostasis, burns and chronic wound treatment, is provided.

The invention relates to neutral phytase gene phyC which comes from microorganism, has enzymolysis phytic acid, phytate and a complex compound thereof and releases mineral nutrition element activity of phosphorus and the like, the optimal pH in enzymatic reaction of an expression product thereof is neutral and is suitable for genetic transformation researches on crops such as mulberry tree, corn and rice and other crops with neutral harvested products. Therefore, with the phyC gene transferred to the mulberry tree, the optimal pH in enzymatic reaction of the expression product is consistent with the pH of the mulberry leaf, in addition, the enzymatic reaction of the expression product of the phyC gene can carry out enzymolysis on the phytic acid, the phytate and the complex compound thereof to release the phosphorus, contributes to absorption and application of the phosphorus by the mulberry tree, reduces fertilization of phosphate fertilizer and pollution of the phosphate on the environment, promotes growth of the mulberry tree; in addition, neutral phytase gene phyC of the invention features relatively high enzymatic activity, approximately 10% higher than the activity of the phytase of the same kind according to measurement.

The present invention relates to methods for reducing fat uptake in the gastrointestinal tract of a mammal in order to prevent a positive energy balance, weight gain, overweight and obesity, and to induce a negative energy balance and weight loss in subjects who wish to reduce their body weight. In particular, food and/or beverage ingredients and dietary supplements of the present invention comprises flaxseeds useful for increasing faeca fat excretion from the gastrointestinal tract.

A hot and cold water-dispersible dry-milled composition including phytosterol-surfactant conglomerate (PSC) particles which include a blend of dry microparticulate non-ester phytosterols and a dry binary surfactant. The composition further optionally includes one or more additional dry ingredients such as anti-caking agents, anti-foam agents, natural and artificial sweeteners, non-dairy creamers and flavoring agents.

The invention discloses a wound treatment material which comprises a fiber. The wound treatment material is characterized in that the fiber comprises a polymer shown as the following structural formula (please see the formula in the description), wherein R is at least one selected from a group composed of -NH2, -OCH2CH2OH, -OCH2CH2CH2OH, -OH, -ONa, -OK and -OCa, m, n and p represent the quantity percentages of corresponding repetitive units in a polymer molecule respectively and meet the following relational expressions that m+n+p=1 and p/(m+n+p)=0.05-0.30, the substitution degree D is defined to be equal to m/(m+n+p), the overall substitution degree of the fiber is defined as Ds, the substitution degree of the polymer at the center point of the cross section of the fiber is defined as Do, the substitution degree of the polymer at the edge of the cross section of the fiber is defined as Dx, and Ds, Do and Dx meet the following relational expressions that Ds=0.09-0.8 and Do/Dx=0-0.7.

Asthma is an inflammatory disease of the airways in the lungs and bronchial tubes, the lower airway, that impairs breathing, causes wheezing, coughing and excess mucus and phlegm production. Asthma is the source of about one-fourth of all emergency room admissions. Throat lozenges and orally-retained liquids, such as syrups, containing magnesium are used in the invention to rapidly terminate asthma attacks and prevent asthma attacks. Magnesium lozenges and magnesium orally-retained liquids are effective in asthma rescue. Treatment of asthma with orally-retained magnesium, an essential human nutrient, is much safer than treatment by drugs yet they appear as effective as current drugs. An added benefit from magnesium treatment is relaxation. A preferred composition is 100 mg of magnesium from 400 mg magnesium chloride in a 4-gram lozenge. Magnesium lozenges or orally-retained liquids are administered as needed to treat asthma attacks or prevent incipient asthma attacks. Throat lozenges and orally-retained liquids of any pharmaceutically acceptable composition containing any pharmaceutically acceptable compound of magnesium are disclosed and claimed as effective in the treatment and prevention of asthma.

The invention features a method for treating cancer by administering a double-stranded nucleic acid molecule against a CX gene selected from the group consisting of C14orf78, MYBL2, UBE2S and UBE2T. The invention also features products, including the double-stranded nucleic acid molecules and vectors encoding them, as well as compositions comprising the molecules or vectors, useful in the provided methods. The methods of the invention are suited for the treatment of cancers including lung cancer, breast cancer, bladder cancer, esophagus cancer, prostate cancer, cholangiocellular carcinoma and testicular seminoma.

The invention discloses a method for determining alternating injection time of polymer flooding. The method comprises the step of determining injection time 1, injection time 2 and injection time 3 according to the changes of moisture content and shunt rate of an oil-displacement system in a high-permeability layer, wherein the injection time 1 is a corresponding period when the moisture content of output liquid reaches a certain value, the injection time 2 is a corresponding period when the shunt rate of the oil-displacement system in the high-permeability layer is suddenly changed, and the injection time 3 is a corresponding period when the shunt rate of the oil-displacement system in the high-permeability layer is in a rising trend and becomes flat. According to the method, the viscosity of a new oil-displacement system corrected to be injected in the injection time 1 is larger than that of the injected oil-displacement system, the viscosity of a new oil-displacement system corrected to be injected in the injection time 2 is smaller than that of the oil-displacement system corrected to be injected in the injection time 1, and the viscosity of a new oil-displacement system corrected to be injected in the injection time 3 is smaller than that of the oil-displacement system corrected to be injected in the injection time 2; and different oil replacement effects of chemically flooded heterogeneous reservoirs can be achieved, and the development degree of a low-permeability layer is improved.

Method and material for spectroscopic detection of organic chemicals. The material is a substantially optically transparent solid, such as ZnS, having a high surface area for adsorption of an analyte, such as organic chemical vapors. The solid material preferably has metal nanoparticles, such as gold, silver or copper nanoparticles, deposited on the surface for signal enhancement. A template compound, such as cetyl trimethyl ammonium bromide and alkoxylate block polymers, may be used during the material synthesis, such as reacting zinc chloride and sodium sulfide in the presence of the template compound, and later removed through calcination and washing to achieve the high surface area. The method of use includes collecting an analyte on the material and detecting the spectroscopic response of the analyte while it is collected on the surface. The mechanism of collection may include adsorbing, absorbing, and preconcentrating. Preferably, the spectroscopic response is selected from infrared spectra or ultraviolet-visible spectra.

The invention discloses a medical non-woven fabric with high permeability. The medical non-woven fabric is characterized in that base cloth is prepared by modified alginate fibers and viscose fibers,and the base cloth is prepared by finishing through a finishing liquid; a mass ratio of the modified alginate fibers to the viscose fibers is 1: 2-3; the non-woven fabric is prepared by the followingsteps of step 1, mixing the modified alginate fibers and the viscose fibers according to the mass ratio, carrying out opening, impurity removal and net forming on blowing-carding equipment and obtaining the base cloth on a non-woven needled sample weaving machine; and step 2, carrying out finishing on the base cloth in the finishing liquid to obtain the non-woven fabric. According to the medical non-woven fabric, the non-woven fabric prepared by mixing the modified alginate fibers and the viscose fibers is used as the base cloth, the modified alginate fibers and the viscose fibers have excellent air permeability and skin friendliness, and are made in a weaving mode, so that the obtained base cloth has extremely high air permeability; the base cloth is finished through the special finishingliquid, so that the antibacterial property and softness of the non-woven fabric can be effectively improved; and the high-permeability non-woven fabric with the excellent antibacterial effect is obtained and is suitable for the medical field.